ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SBTX Skinbiotherapeutics Plc

9.25
0.00 (0.00%)
23 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.25 9.00 9.50 9.25 9.25 9.25 186,038 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 132k -2.84M -0.0163 -5.67 16.1M
Skinbiotherapeutics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherapeutics was 9.25p. Over the last year, Skinbiotherapeutics shares have traded in a share price range of 7.25p to 29.50p.

Skinbiotherapeutics currently has 174,004,323 shares in issue. The market capitalisation of Skinbiotherapeutics is £16.10 million. Skinbiotherapeutics has a price to earnings ratio (PE ratio) of -5.67.

Skinbiotherapeutics Share Discussion Threads

Showing 1551 to 1571 of 23475 messages
Chat Pages: Latest  63  62  61  60  59  58  57  56  55  54  53  52  Older
DateSubjectAuthorDiscuss
17/4/2018
15:59
Very good key points in the interview I don't mind admitting I wasn't aware of...."Great technology can be screwed up by formulation. " Clearly more important than perhaps credited and gel's and lotion formulation to be tested.
elrico
17/4/2018
15:02
New interview with Cath just out.

'Huge milestone' for SkinBioTherapeutics with cream formulation success

parob
17/4/2018
13:37
Dr. Cath and her professor are a CLASS ACT they know their stuff inside-out..the development of the Gel and Lotion is just a formality. and an even larger resulting market along with many more opportunities. The ingredients of the cosmetic cream could be used perhaps in Sun Screen lotion providing protection from infections while giving the skin tone behind the tan more radiance.

There are so many angles on these products it has to become a market leader in at least three sectors...imo.

bobalot
17/4/2018
09:43
Impressive progress and this continues on quite a steep upward trend. Too early for an N4P effect or timing ahead of trials just about right? Either way happy to be in here at such low prices.
rathean
17/4/2018
09:18
Human trials start in Q3 so they have just a few months to finalise the formulations for the Gel and Lotion....Dr. Cath looks very confident imo.

Buying has now started at 11p:

Skinbiotherapeutics PLC
LON: SBTX
11,00 GBX +1,25 (12,82%)
17.04, 09:11

bobalot
17/4/2018
09:14
Yes so great news. So direct correlation of the protein in the skin to the amount of probiotic lysate extract in the cream. That clearly helps them accurately determine the level of dosing required to ensure the desired level of effectiveness of the product. Stability tests of the cream to follow. I guess another key test as you don't want the ingredients separating out in the bottle/transit etc. They are also effectively saying that the gel and lotion haven't quite reached their high levels of satisfaction yet. So more work to continue on refining those products.
toadhall1
17/4/2018
08:01
tHIS PART IS VERY INTERESTING shows a direct correlation, meaning the strength or effectiveness of the cream to enhance the skins barrier to infection can be controlled. And there will be three cosmetic products presented as a cream, gel and lotion....all very large target markets imo.


The data further showed a direct correlation between the amount of SkinBiotix(R) within the cream and the level of the protein present. Work on creating skin lotion and gel formulations is ongoing.

bobalot
17/4/2018
07:09
Confirmation of the formulation of creams may help to nudge this share in the right direction and become the beginning of a share price rerate given all the other good news in the pipeline.gla
nig1954
16/4/2018
15:39
Why is that Parob, has there been an Investor Show to-date that sparked a scintilla of interest in our beloved SBTX and OPTI?
owenmo
15/4/2018
16:38
I'll be there and will feedback anything worthwhile
onedayrodders
15/4/2018
12:42
SkinBioTherapeutics will be exhibiting at the UK Investor Show on Sat 21st April. Should hopefully drum up more investor interest in the company.
parob
15/4/2018
12:33
The Role of the Skin Microbiome in Atopic Dermatitis (Eczema)hTTps://www.slideshare.net/mobile/LauraBerry22/the-role-of-the-skin-microbiome-in-atopic-dermatitis-eczema
parob
14/4/2018
10:55
Elrico

Great post and insight.

My comments are more from a trading activity view.

The last week or so we've started to see increased volume and an improvement on the share price performance.

A close above 10p could see a decent run purely as it will have broken through ceiling. Some very nice buys been going through.

I'm heavily in here already but am very tempted to add at these levels.

I still think a commercial tie up could be done prior to the human trials so the Mn partner can have input into them.

Let's not forget the dosage tests etc have been done in human skin samples already so what are the chances of success?

At this current market cap it could be a real winner in time.

S

shrewdmole
13/4/2018
16:12
Elrico very good and informative views...SBTX is in the right pace at exactly the right time...The article published yesterday about developments in the Korean market underscores that view.

Beyond beauty: Korean makeup provides 'cosmeceuticals'

bobalot
13/4/2018
15:44
At the risk of falling into a trap...Paul - post 1486 is NOT a "Hybridan article" they are my personal views, with valuations of Hybridan as an illustration of SkinBiotix's huge potential. From memory, Hybridans valuation was prior the proof of concept, scientific validation, hence the high risk it put on SkinBiotix of failing. History now tells us the science works, thus we wait the final validation; human trials data. I also wanted to put across industry valuation (with assumptions all goes according to plan). I think we all agree SBTX has huge potential and by following the parent company's commercial footprint, SBTX will almost certainly multi-multi-bag from here in due course; but patience will be required. We must learn from OPTI's story, MN partners move at their pace, not at PI's pace.

There are no further funding requirements, no marketing spend, and ongoing R&D done on the cheap via UoM labs, this all points to low PLC costs where partners pickup the marketing tab while SBTX reaps the royalties, etc.

IMHO Cath has learned from SOH, which is why I suggest the MTA is a smart move and one that has the potential to speed up the commercial process by essentially getting the DD out of the way ahead of the human trial data. The question remains, is it J&J or another global corporate? The more I think about it, the more I'm inclined to think I am wrong in my first guess (J&J) because logic suggests J&J have been working very closely with SkinBiotix since June 2014, so I think it's a safe assumption there could be another global corporate in line to use SBTX IP. IF I am correct, this is a fantastic development for SBTX.

elrico
13/4/2018
14:56
Coming from the master of repetitive info that would be quite funny if it wasn't so foolish. How is it old repetitive rubbish? Have i missed something? Don't you agree with the hybridan valuation?
paulhoodwinked
13/4/2018
14:50
Indeed risky

Holding firm here and at OPTI, should be great few years coming up

onedayrodders
13/4/2018
14:45
If you like reading out-of date repetition then keep reading that rubbish.
bobalot
13/4/2018
14:34
Opportunity to buy at IPO price or below has now gone imo. Next 12 months will see some great science translated in to commercial interest. Last RNS shows the corporate interest even before human studies. Science is clearly well sought after. People just need to be aware of how long it takes to build a business which relies on license deals. Patience will make a lot of money for people here and with Opti (even from 700% up from IPO 3 years ago... things are just beginning commercially over there)
riskybusiness1
13/4/2018
14:12
WOW instant arbitrage on current quote !

9.50 offer 10.00 bid

onedayrodders
13/4/2018
13:03
A small top up for me today. Surprised this hasn't moved up yet based on all the buying. Hoping 9.75p is the higher low going in.
parob
Chat Pages: Latest  63  62  61  60  59  58  57  56  55  54  53  52  Older

Your Recent History

Delayed Upgrade Clock